TFB 15: Die Bedeutung des Komplementspaltproduktes C3a als diagnostischer Frühmarker in der Sepsis

本项目的目的是将炎症介质C3 a作为脓毒症患者诊断标志物的重要性的结果转移到临床应用中。这些数据是在244“慢性炎症”合作研究中心获得的。为了验证初步结果，进行了一项前瞻性多中心研究，其中来自慕尼黑-戈斯哈德恩、曼海姆、海德堡、马格德堡和汉诺威的8个不同的外科、内科和麻醉重症监护室参与了研究。为了关注该综合征的最初阶段，本研究调查了具有发展脓毒症高风险的不同患者组。除了分析补体系统的激活外，还研究了炎症介质IL-6和降钙素原的释放。最关键的问题是血液中不同免疫学参数的测定是否允许早期诊断败血症，即在临床体征发展之前。工业合作伙伴Biognosis生产了一种新型的自动化C3 a床边检测，将在参与的重症监护病房进行评估。

The aim of this project is to transfer the results concerning the importance of the inflammatory mediator C3a as a diagnostic marker in septic patients into a clinical application. These data were obtained in the collaborative research centre 244 "Chronic Inflammation". To validate the preliminary results, a prospective multicenter study is performed, in which eight different surgical, internal and anesthesiologic intensive care units from Munich-Goßhadern, Mannheim, Heidelberg, Magdeburg and Hannover participate. To focus on the very beginning of the syndrome, different patient groups with a high risk to develop sepsis are investigated in this study. In addition to the analysis of the activation of the complement system the release of the inflammatory mediators IL-6 and procalcitonin is investigated. The most critical question is whether the determination of the different immunological parameters in blood allow to diagnose sepsis early i.e. before clinical signs develop. The industrial partner Biognosis produced a novel, automated C3a bedside-assay which will be evaluated in the participating intensive care units.